Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cv4ZirB
via IFTTT